A Changing Landscape
As the pharmaceutical industry has evolved and grown, so too has its ability to develop child-friendly formulations
Maryam Mahdi | | Interview
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
For much of the 20th century, research, regulations and formulation development have focused on treating diseases in adults, leading some to describe children as “therapeutic orphans” (1). With fewer options available and with dosages and administration routes that failed to satisfy the pediatric demographic, there was a clear need – and a gap in the pharmaceutical market. Here, Matt Ling, Director of Scientific Services, Oral & Specialty Delivery, and Andrew Parker, Senior Program Manager, Early-Phase Development, Oral Drug Delivery – both at Catalent – consider the progress the industry has made in the development of pediatric formulations and the issues that developers still face. And perhaps most importantly, they define the steps that need to be taken to bring truly child-optimized medicines to market faster.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.